Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Triple-negative breast cancer: risk factors to potential targets.

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA.

Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Review.

2.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

3.

What is triple-negative breast cancer?

Irvin WJ Jr, Carey LA.

Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Review.

PMID:
19008097
4.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
5.

Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.

Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J.

Oncol Rep. 2008 Oct;20(4):987-94.

PMID:
18813844
6.

Clinicopathological characteristics of triple-negative breast cancers.

Sasaki Y, Tsuda H.

Breast Cancer. 2009;16(4):254-9. doi: 10.1007/s12282-009-0153-5. Epub 2009 Aug 6.

PMID:
19657711
7.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

8.

Triple negative tumours: a critical review.

Reis-Filho JS, Tutt AN.

Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Review.

PMID:
18171422
9.

"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R.

Semin Oncol. 2011 Apr;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Review.

PMID:
21421115
10.

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.

Venkitaraman R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Review.

PMID:
20131996
11.

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.

Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T.

J Surg Oncol. 2008 Jan 1;97(1):30-4.

PMID:
17929254
12.

Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Bosch A, Eroles P, Zaragoza R, ViƱa JR, Lluch A.

Cancer Treat Rev. 2010 May;36(3):206-15. doi: 10.1016/j.ctrv.2009.12.002. Epub 2010 Jan 8. Review.

PMID:
20060649
13.

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.

Kurebayashi J.

Breast Cancer. 2009;16(4):275-80. doi: 10.1007/s12282-009-0111-2. Epub 2009 May 1.

PMID:
19408071
14.

Triple-negative/basal-like breast cancer: review.

Rakha EA, Ellis IO.

Pathology. 2009 Jan;41(1):40-7. doi: 10.1080/00313020802563510. Review.

PMID:
19089739
15.

Triple-negative breast cancer: novel therapies and new directions.

Pal SK, Mortimer J.

Maturitas. 2009 Aug 20;63(4):269-74. doi: 10.1016/j.maturitas.2009.06.010. Epub 2009 Jul 25. Review.

PMID:
19632796
16.

Pharmacotherapy of triple-negative breast cancer.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Review.

PMID:
19640211
17.

Triple negative breast cancer: from molecular portrait to therapeutic intervention.

Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N.

Crit Rev Eukaryot Gene Expr. 2010;20(1):17-34. Review.

PMID:
20528735
18.

Triple negative breast cancer: clinicopathological characteristics and treatment strategies.

Akiyama F, Iwase H.

Breast Cancer. 2009;16(4):252-3. doi: 10.1007/s12282-009-0140-x.

PMID:
19506994
19.

Triple-negative breast cancer: current state of the art.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.

Tumori. 2010 Nov-Dec;96(6):875-88. Review.

20.

Potential chemotherapy options in the triple negative subtype of breast cancer.

Altundag K, Harputluoglu H, Aksoy S, Gullu IH.

J Clin Oncol. 2007 Apr 1;25(10):1294-5; author reply 1295-6. No abstract available.

PMID:
17401026

Supplemental Content

Support Center